Home -> Law Blog Directory -> Patent Law Blogs -> IPBiz
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: IPBizThe valuation of claims of patents
By Lawrence B. Ebert, Esq.
I would believe that many people want to look at the IP market the way we have looked at every other marketplace the last half century or so. Now pursuing a thesis within Patent Valuation I can also conclude that academics sometime try and fit a square peg in a round hole with applying classical financial theories to an IP setting. The most striking being that not even all authors are clear on what a patent actually is and many also dive head into the logic of patents=products. Whether you are pro or con NPEs they at least crush that myth with their business model. Looking at a (IP) market with the view that it is a means of generating revenue elsewhere (i.e. products or services), then it is not difficult to see how people are working hard to closing the NPEs "loophole".
At least square pegs and round holes are tangible. One Stanford academic invoked a non-existent article in the New York Times to justify his IP theories. See 8 JMRIPL 80.
Separately, it's hard to see the evidence for a "loophole" as to NPE's. Patent law is, and has been, about the exchange of knowledge for a right to exclude. Never said anything about the patent holder having to make a commercial product, or even worrying about whether a commercial product could be made. People who think of "loopholes" here don't understand what patent law is about.
Additionally, on the valuation front, LBE wrote in 2005 text including-->
Chesbrough addresses IP valuation and emphasizes that IP can be valued only in the context of a business model. He notes: "[IP enthusiasts] claim that IP has enormous potential value, if only companies would pay proper attention to managing it. These proponents have half a point. There is indeed latent economic value in companies' IP, and some of that value has not been realized. Yet most patents are worth very little, and it is hard to know in advance which patents are valuable and which are not. Moreover, the claim as it stands is incomplete, because it assumes that technology assets have some inherent value, independent of any business model used to employ them. Technology by itself has no inherent value; that value only arises when it is commercialized through a business model. As with xerography and some other PARC spin-off technologies, the same technology commercialized through two different business models will yield two different economic outcomes. Much of [other people's] work on managing IP assumes that there is some objective value for a technology separate from how it is commercialized."
**See also
IEEE to get into the patent pool business?
Full post as published by IPBiz on December 16, 2008 (boomark / email).
Paxil Lawsuit
Paxil Claims, Lawsuits, and Injuries
Wells Fargo and Rels Valuation
Face Home Evaluation Class Action
False Claims
Attorney Robert Arledge ordered to pay $5.8 million after making false Fen Phen settlement claims.
LINA - Cigna Life Insurance Company of North America Disability Claims
LINA Insurance alleging violations of disability insurance claims.
Bayer to Pay $3.3 Million To Settle One A Day Vitamin Claims
Bayer to Pay $3.3 Million To Settle One A Day Vitamin Claims
Archdiocese of Denver
Settles 5.5 million in claims
BP
Settles More Claims From Texas Refinery Explosion

Gerzog: The New Regs on Alternative Date Valuation
Federal Courts Can't Use Supplemental Jurisdiction To Hear Claims Under Foreign Patents
Alternate Valuation Date Regulations
Never Answer the Valuation Question with a Specific Number








